Literature DB >> 6206139

NK recognition of target structures: is the transferrin receptor the NK target structure?

R A Newman, J F Warner, G Dennert.   

Abstract

That the transferrin receptor acts as a target antigen for human NK cells has previously been suggested. In this study we used two models to examine the hypothesis that the transferrin receptor is recognized by NK cells. In the first model, we employed mouse cloned NK cells in conjunction with the species-specific monoclonal antibody R17 217, which binds to the murine transferrin receptor. We show that there is no correlation between the amount of transferrin receptor expressed on targets and the susceptibility of these targets to NK lysis or NK binding in cold target competition assays. In the second model, we used human NK cells and transferrin receptor-positive transformants as targets. These transformants were derived from mouse L cells transfected with human DNA and selected for the presence of human transferrin receptor. Results show that, in contrast to the mouse system, there is a correlation between the expression of the human transferrin receptor on targets and the ability of these targets to competitively inhibit the lysis of K562 by NK cells. However, because inhibition is not complete, other cell surface antigens probably play a role in human NK-target interactions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206139

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Different functional domains on the transferrin receptor molecule defined by monoclonal antibodies.

Authors:  J A Lopez Guerrero; J M Redondo; B Alarcón; F Sánchez-Madrid; M Rodríguez Moya; M Ortíz de Landazuri; C Bernabeu; M Fresno
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

Review 2.  Cytotoxic effector cells of the immune system.

Authors:  P Groscurth
Journal:  Anat Embryol (Berl)       Date:  1989

Review 3.  The role of iron and iron binding proteins in lymphocyte physiology and pathology.

Authors:  J D Kemp
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

4.  Lysis of small cell carcinoma of the lung tumor cell lines by gamma interferon-activated allogeneic peripheral blood mononuclear cells: abrogation of killing by pretreatment of tumor cells with gamma interferon.

Authors:  E D Ball; K E Nichols; O S Pettengill; G D Sorenson; M W Fanger
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Pulmonary alveolar macrophages in patients with sarcoidosis and hypersensitivity pneumonitis: characterization by monoclonal antibodies.

Authors:  C Agostini; L Trentin; R Zambello; M Luca; M Masciarelli; A Cipriani; G Marcer; G Semenzato
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

6.  C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition.

Authors:  L L Baum; B Johnson; S Berman; D Graham; C Mold
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

7.  Laminin inhibits the recognition of tumor target cells by murine natural killer (NK) and natural cytotoxic (NC) lymphocytes.

Authors:  J C Hiserodt; K A Laybourn; J Varani
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

8.  Natural killer cells in peripheral blood and the mixed lymphocyte response: interaction with the transferrin receptor.

Authors:  M Salmon; P A Bacon; S P Young
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

9.  Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells.

Authors:  K R Bridges; B R Smith
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

10.  Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes.

Authors:  R Zambello; T Chisesi; C Agostini; L Trentin; M Masciarelli; G Gasparotto; M Vespignani; G Casorati; R Foa; G Semenzato
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.